August 11, 2021 GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights July 29, 2021 GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11 July 26, 2021 GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test July 8, 2021 GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey May 14, 2021 GBS Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights April 15, 2021 GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update December 28, 2020 GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering
August 11, 2021 GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
July 29, 2021 GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11
July 26, 2021 GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
July 8, 2021 GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
June 8, 2021 Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
April 15, 2021 GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
